Covid-19: US agencies involve pause in Johnson & Johnson vaccine
US health authorities are calling for an interruption within the use of the Johnson & Johnson Covid-19 vaccine, after reports of extremely rare blood coagulation cases.
The Food and Drug Administration (FDA) said six cases in 6.8 million doses had been reported and it had been acting "out of an abundance of caution".
Johnson & Johnson said it had been also delaying vaccine rollout in Europe.
The US move follows similar rare cases within the AstraZeneca vaccine, which has prompted some curbs in its use.
The US has far and away the foremost confirmed cases of Covid-19 - quite 31 million - with quite 562,000 deaths, another world high.
The picture for the virus within the US is complicated, though, with some areas within the north seeing surges in infections, the south less, and with the figures not always reflecting inoculation numbers.
The Johnson & Johnson jab was approved within the US on 27 February and its use has been more limited thus far than that of the Pfizer-BioNTech and Moderna doses.
Nevertheless, the govt had hoped for many thousands of vaccinations of the jab hebdomadally because it is single-shot and its storage at common refrigerator temperatures makes it easier to distribute.
Also Read: Brazil Breaches 90,000 Covid-19 Cases during a Day
Johnson & Johnson statement
Johnson & Johnson, a US health care company, issued a press release saying that safety was its "number one priority" which it shared "all adverse event reports" with the health authorities.
It added: "We are aware that thromboembolic events including those with thrombocytopenia are reported with Covid-19 vaccines. at the present , no clear causal relationship has been established between these rare events and therefore the Janssen (J&J) Covid-19 vaccine."
It also said that it had been reviewing cases with European health authorities.
"We have made the choice to proactively delay the rollout of our vaccine in Europe," it said.
For all latest news updates, stay hooked on to Fever Of News.
0 comentários: